For growth investors
Benchmark scaling companies against the market that prices them
A growth company is eventually priced by the public comparables and the acquirers in its sector, whatever the last round said. NeuraCap keeps that comparison live: a peer group built on business substance, KPI benchmarks shown as a distribution, and a valuation cross-check against transactions that actually happened.
- Price a round against the market
- Benchmark KPIs to a real peer set
- Keep portfolio companies measured
- Test an exit thesis on real deals
- Brief a founder with evidence
The current state
What slows this down today
The private mark and the public market drift apart
A round priced eighteen months ago sits against a peer set that has since re-rated. Nobody re-checks the gap until the next raise forces it, and by then it is a negotiation.
The peer set changes depending on who is arguing
In the pitch the company is compared to the category leaders. In diligence it is compared to the laggards. Without a peer group built on business substance, the multiple argument is preference.
Benchmarking is built once and then goes stale
The benchmark pack is assembled for the investment and refreshed when someone has a spare week. Reviews then run on a comparison describing a market that has already moved.
The exit thesis is asserted rather than evidenced
Saying an asset will clear at a given revenue multiple is a claim about the transaction record. It is usually made from memory of two deals rather than the record itself.
The change
How NeuraCap changes the workflow
KPI benchmarking
A distribution, not a flattering average
- The problem
- Benchmarks get quoted as a single number, which hides the spread that determines whether a company is really outperforming.
- Why it matters
- A company at the median on growth and the twentieth percentile on margin is a different investment from one at the eightieth on both.
- In NeuraCap
- NeuraCap builds a peer group from business substance, benchmarks the company against it and reports medians and percentiles, so the position in the distribution is visible.
- What you get
- A KPI benchmark table and peer comparison, with the reason each company is in the set shown alongside it.
- The decision it enables
- Where to push a management team, and which part of the story the next buyer will actually pay for.
Pricing and exit evidence
What the market has paid for companies like this
- The problem
- Round pricing and exit expectations are argued from a handful of remembered deals rather than from the transaction record.
- Why it matters
- The gap between a private mark and the public comparables is the risk in the position, and it is only visible if someone keeps measuring it.
- In NeuraCap
- A primary valuation basis is stated for the sector with EV/Revenue as a cross-check, and precedent transactions are screened by sub-sector and size band, each figure confirmed against two sources.
- What you get
- A football-field valuation range and a precedent table showing where comparable assets cleared and which buyer types paid above the median.
- The decision it enables
- What to pay into a round, and when the gap to the public market has grown far enough to act on.
From a company to a live benchmark
Frame the peer group
Public companies are matched on what the business actually does. You keep, cut or add names, so the comparison is one you would defend to a founder.
Benchmark the KPIs
Growth, margin and the operating metrics NeuraCap holds are placed against that peer group as medians and percentiles, not a single headline average.
Cross-check the pricing
A primary valuation basis is stated for the sector, with EV/Revenue as a cross-check. Plausibility gates stop one broken comparable flattering the range.
Test the exit argument
Screen precedent transactions by sub-sector and size band to see where comparable assets changed hands, and which buyers paid above the median.
Keep it current
Analysis is refreshed rather than rebuilt, so a portfolio review starts from a live comparison instead of a slide from two quarters ago.
The underlying pieces are public company analysis for comparables and KPI benchmarking, valuation analysis for the range, industry intelligence for the sector picture, and the Financial Assistant for the questions a partner asks in the meeting.
The deliverable
What you take to the partner meeting
- A peer group built on business substance, with the reasoning shown
- KPI benchmarks as medians and percentiles, not a single average
- A valuation range with a stated basis and an EV/Revenue cross-check
- Precedent transactions for the sub-sector and size band
- A sector read covering what moved and what is driving it
- An export to PDF or PPTX for the partner meeting
When the same company is being screened for control rather than growth capital, the workflow is the one in NeuraCap for private equity.
Proof
Test the method on published research
Industry Sector Outlook
Where a sector is, how wide the valuation spread has become, and who has been buying growth.
Industry Events & M&A Update
Announcements and deal activity across the sectors we cover, every two weeks.
Sectors and sources
Which sectors are covered, which source classes stand behind a figure, and where the limits sit.
Straight answers
The objections growth investors raise first
- Can we use this to mark the portfolio for reporting?
- It is evidence for your own process, not a formal valuation. NeuraCap does not produce an appraisal, a fairness opinion or a valuation opinion for financial reporting, and creates no fiduciary relationship. The mark stays yours.
- Our companies are private. Where does the benchmark come from?
- The company data is user-provided and then enriched, and is labelled that way. The market it is measured against is public: fundamentals from SEC EDGAR filings where applicable, consensus estimates for revenue, EBITDA and EPS, market price data and a structured M&A transaction record. Medians, percentiles and multiples are calculated from those inputs.
- Every founder says their comparable set is unique.
- Often fairly. That is why the peer group is editable and the reasoning for each inclusion is visible. The argument moves from whether the comparison is fair to which names belong in it.
- Does it predict which companies will win?
- No. NeuraCap reads what the evidence shows, in calibrated language, rather than asserting causation or forecasting an outcome. Nothing on the platform is a recommendation to buy or sell a security, or an offer or solicitation.
Get your custom-built strategic insights report today.
Public or private, any sector. Tell us the company and what you need to understand.